Cargando…

Development and Validation of a Novel Risk Prediction Model Using Recursive Feature Elimination Algorithm for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Patients With Severe Acute Exacerbation

Background: Patients with chronic hepatitis B (CHB) with severe acute exacerbation (SAE) are at a progression stage of acute-on-chronic liver failure (ACLF) but uniform models for predicting ACLF occurrence are lacking. We aimed to present a risk prediction model to early identify the patients at a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Mingxue, Li, Xiangyong, Lu, Yaxin, Jie, Yusheng, Li, Xinhua, Shi, Xietong, Zhong, Shaolong, Wu, Yuankai, Xu, Wenli, Liu, Zifeng, Chong, Yutian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591055/
https://www.ncbi.nlm.nih.gov/pubmed/34790679
http://dx.doi.org/10.3389/fmed.2021.748915
_version_ 1784599132325806080
author Yu, Mingxue
Li, Xiangyong
Lu, Yaxin
Jie, Yusheng
Li, Xinhua
Shi, Xietong
Zhong, Shaolong
Wu, Yuankai
Xu, Wenli
Liu, Zifeng
Chong, Yutian
author_facet Yu, Mingxue
Li, Xiangyong
Lu, Yaxin
Jie, Yusheng
Li, Xinhua
Shi, Xietong
Zhong, Shaolong
Wu, Yuankai
Xu, Wenli
Liu, Zifeng
Chong, Yutian
author_sort Yu, Mingxue
collection PubMed
description Background: Patients with chronic hepatitis B (CHB) with severe acute exacerbation (SAE) are at a progression stage of acute-on-chronic liver failure (ACLF) but uniform models for predicting ACLF occurrence are lacking. We aimed to present a risk prediction model to early identify the patients at a high risk of ACLF and predict the survival of the patient. Methods: We selected the best variable combination using a novel recursive feature elimination algorithm to develop and validate a classification regression model and also an online application on a cloud server from the training cohort with a total of 342 patients with CHB with SAE and two external cohorts with a sample size of 96 and 65 patients, respectively. Findings: An excellent prediction model called the PATA model including four predictors, prothrombin time (PT), age, total bilirubin (Tbil), and alanine aminotransferase (ALT) could achieve an area under the receiver operating characteristic curve (AUC) of 0.959 (95% CI 0.941–0.977) in the development set, and AUC of 0.932 (95% CI 0.876–0.987) and 0.905 (95% CI 0.826–0.984) in the two external validation cohorts, respectively. The calibration curve for risk prediction probability of ACLF showed optimal agreement between prediction by PATA model and actual observation. After predictive stratification into different risk groups, the C-index of predictive 90-days mortality was 0.720 (0.675–0.765) for the PATA model, 0.549 (0.506–0.592) for the end-stage liver disease score model, and 0.648 (0.581–0.715) for Child–Turcotte–Pugh scoring system. Interpretation: The highlypredictive risk model and easy-to-use online application can accurately predict the risk of ACLF with a poor prognosis. They may facilitate risk communication and guidetherapeutic options.
format Online
Article
Text
id pubmed-8591055
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85910552021-11-16 Development and Validation of a Novel Risk Prediction Model Using Recursive Feature Elimination Algorithm for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Patients With Severe Acute Exacerbation Yu, Mingxue Li, Xiangyong Lu, Yaxin Jie, Yusheng Li, Xinhua Shi, Xietong Zhong, Shaolong Wu, Yuankai Xu, Wenli Liu, Zifeng Chong, Yutian Front Med (Lausanne) Medicine Background: Patients with chronic hepatitis B (CHB) with severe acute exacerbation (SAE) are at a progression stage of acute-on-chronic liver failure (ACLF) but uniform models for predicting ACLF occurrence are lacking. We aimed to present a risk prediction model to early identify the patients at a high risk of ACLF and predict the survival of the patient. Methods: We selected the best variable combination using a novel recursive feature elimination algorithm to develop and validate a classification regression model and also an online application on a cloud server from the training cohort with a total of 342 patients with CHB with SAE and two external cohorts with a sample size of 96 and 65 patients, respectively. Findings: An excellent prediction model called the PATA model including four predictors, prothrombin time (PT), age, total bilirubin (Tbil), and alanine aminotransferase (ALT) could achieve an area under the receiver operating characteristic curve (AUC) of 0.959 (95% CI 0.941–0.977) in the development set, and AUC of 0.932 (95% CI 0.876–0.987) and 0.905 (95% CI 0.826–0.984) in the two external validation cohorts, respectively. The calibration curve for risk prediction probability of ACLF showed optimal agreement between prediction by PATA model and actual observation. After predictive stratification into different risk groups, the C-index of predictive 90-days mortality was 0.720 (0.675–0.765) for the PATA model, 0.549 (0.506–0.592) for the end-stage liver disease score model, and 0.648 (0.581–0.715) for Child–Turcotte–Pugh scoring system. Interpretation: The highlypredictive risk model and easy-to-use online application can accurately predict the risk of ACLF with a poor prognosis. They may facilitate risk communication and guidetherapeutic options. Frontiers Media S.A. 2021-11-01 /pmc/articles/PMC8591055/ /pubmed/34790679 http://dx.doi.org/10.3389/fmed.2021.748915 Text en Copyright © 2021 Yu, Li, Lu, Jie, Li, Shi, Zhong, Wu, Xu, Liu and Chong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Yu, Mingxue
Li, Xiangyong
Lu, Yaxin
Jie, Yusheng
Li, Xinhua
Shi, Xietong
Zhong, Shaolong
Wu, Yuankai
Xu, Wenli
Liu, Zifeng
Chong, Yutian
Development and Validation of a Novel Risk Prediction Model Using Recursive Feature Elimination Algorithm for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Patients With Severe Acute Exacerbation
title Development and Validation of a Novel Risk Prediction Model Using Recursive Feature Elimination Algorithm for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Patients With Severe Acute Exacerbation
title_full Development and Validation of a Novel Risk Prediction Model Using Recursive Feature Elimination Algorithm for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Patients With Severe Acute Exacerbation
title_fullStr Development and Validation of a Novel Risk Prediction Model Using Recursive Feature Elimination Algorithm for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Patients With Severe Acute Exacerbation
title_full_unstemmed Development and Validation of a Novel Risk Prediction Model Using Recursive Feature Elimination Algorithm for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Patients With Severe Acute Exacerbation
title_short Development and Validation of a Novel Risk Prediction Model Using Recursive Feature Elimination Algorithm for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Patients With Severe Acute Exacerbation
title_sort development and validation of a novel risk prediction model using recursive feature elimination algorithm for acute-on-chronic liver failure in chronic hepatitis b patients with severe acute exacerbation
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591055/
https://www.ncbi.nlm.nih.gov/pubmed/34790679
http://dx.doi.org/10.3389/fmed.2021.748915
work_keys_str_mv AT yumingxue developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT lixiangyong developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT luyaxin developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT jieyusheng developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT lixinhua developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT shixietong developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT zhongshaolong developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT wuyuankai developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT xuwenli developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT liuzifeng developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation
AT chongyutian developmentandvalidationofanovelriskpredictionmodelusingrecursivefeatureeliminationalgorithmforacuteonchronicliverfailureinchronichepatitisbpatientswithsevereacuteexacerbation